In this interview, Joao discusses the molecules and products he reviews and how important it is to understand how they affect efficacy and safety in patients.
Find out what Kevin Vernarec (QPS) thinks about how outsourcing might change in the future in this expert interview.
Find out what Song Li (Frontage) has to say about the future of bioanalytical outsourcing, in this video interview.
In this interview, Anita Tailor (Merck) discusses biomarker validation and standardization before predicting what the future may hold for biomarker research.
In this Spotlight interview, Franklin Spriggs (KCAS; KS, USA) explains his interest in biomarkers and introduces the technologies and techniques utilized and offered by KCAS.
In this podcast, Kevin Ray (MilliporeSigma) discusses the techniques and technologies utilized in drug metabolism studies for biotherapeutics, and what he believes the future holds for the field.
As part of our focus, we present this podcast where we talk to Mark Savage who discusses how software tools can address certain challenges and bring forward compounds from discovery to development.
In this interview we talk to Timothy Olah (Bristol-Myers Squibb) about his research and role as Group Director. He discusses his group’s responsibility for developing quantitative methods to measure novel therapeutics and biomarkers in discovery.
In this interview, Allena Ji (Sanofi Genzyme; MA, USA) discusses the advantages and challenges of using triple quadrupole mass spectrometry, the challenges associated with increasing biomarker assay sensitivity and how the field may be regulated and standardized.
In this interview with Ragu Ramanathan (Pfizer; NY, USA), Ragu describes his current research focuses in measuring and quantitating drugs and metabolites in animal and human samples. Ragu discusses the key challenges associated with studying drug/drug interactions (DDI), the benefits of current technologies available for studying DDI and what to expect from the upcoming Special Focus Issue from Bioanalysis on ‘Novel LC–MS assays impacting CYP and transporter DDI evaluation’.